Drug Profile


Alternative Names: RVT 103

Latest Information Update: 26 Nov 2016

Price : $50

At a glance

  • Originator Axovant Sciences
  • Class Antidementias; Indans; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease; Lewy body disease

Most Recent Events

  • 07 Nov 2016 Phase-I clinical trials in Alzheimer's disease in Bermuda
  • 07 Nov 2016 Phase-I clinical trials in Lewy body disease in Bermuda
  • 15 Aug 2016 Early research in Alzheimer's disease in Bermuda (unspecified route) after August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top